



Performance Measure Review

ACP supports QPP measure 005: “Heart Failure: Angiotensin-Converting Enzyme Inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction” because there is good evidence that ACE inhibitors and ARBs improve the health of people with heart failure and LVEF < 40%, and the measure aligns with current guidelines and represents high-value care for patients with chronic heart failure.